JP7668742B2 - Ｍｈｃクラスｉｉモデルによる新生抗原の特定 - Google Patents

Ｍｈｃクラスｉｉモデルによる新生抗原の特定 Download PDF

Info

Publication number
JP7668742B2
JP7668742B2 JP2021552549A JP2021552549A JP7668742B2 JP 7668742 B2 JP7668742 B2 JP 7668742B2 JP 2021552549 A JP2021552549 A JP 2021552549A JP 2021552549 A JP2021552549 A JP 2021552549A JP 7668742 B2 JP7668742 B2 JP 7668742B2
Authority
JP
Japan
Prior art keywords
allele
mhc
peptide
cells
neoantigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552549A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020181240A5 (https=
JP2022524328A (ja
JP2022524328A5 (https=
Inventor
トーマス フランシス バウチャー
ブレンダン ブリック－サリバン
ジェニファー バズビー
ミン デュク カオ
マシュー ジョセフ デイビス
ローレン エリザベス ヤング
ジョシュア マイケル フランシス
クリスティーヌ パーマー
モイツァ スコベルネ
ロマン イェレンスキー
Original Assignee
グリットストーン バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリットストーン バイオ インコーポレイテッド filed Critical グリットストーン バイオ インコーポレイテッド
Publication of JP2022524328A publication Critical patent/JP2022524328A/ja
Publication of JPWO2020181240A5 publication Critical patent/JPWO2020181240A5/ja
Publication of JP2022524328A5 publication Critical patent/JP2022524328A5/ja
Priority to JP2025066884A priority Critical patent/JP2025114587A/ja
Application granted granted Critical
Publication of JP7668742B2 publication Critical patent/JP7668742B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/044—Recurrent networks, e.g. Hopfield networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/044—Recurrent networks, e.g. Hopfield networks
    • G06N3/0442—Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/045—Combinations of networks
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/0464—Convolutional networks [CNN, ConvNet]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/04—Architecture, e.g. interconnection topology
    • G06N3/048—Activation functions
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/082—Learning methods modifying the architecture, e.g. adding, deleting or silencing nodes or connections
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G06N3/09—Supervised learning
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
  • Computational Linguistics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
JP2021552549A 2019-03-06 2020-03-06 Ｍｈｃクラスｉｉモデルによる新生抗原の特定 Active JP7668742B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025066884A JP2025114587A (ja) 2019-03-06 2025-04-15 Ｍｈｃクラスｉｉモデルによる新生抗原の特定

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814801P 2019-03-06 2019-03-06
US62/814,801 2019-03-06
US201962826822P 2019-03-29 2019-03-29
US62/826,822 2019-03-29
PCT/US2020/021508 WO2020181240A1 (en) 2019-03-06 2020-03-06 Identification of neoantigens with mhc class ii model

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025066884A Division JP2025114587A (ja) 2019-03-06 2025-04-15 Ｍｈｃクラスｉｉモデルによる新生抗原の特定

Publications (4)

Publication Number Publication Date
JP2022524328A JP2022524328A (ja) 2022-05-02
JPWO2020181240A5 JPWO2020181240A5 (https=) 2023-03-13
JP2022524328A5 JP2022524328A5 (https=) 2023-03-13
JP7668742B2 true JP7668742B2 (ja) 2025-04-25

Family

ID=72338461

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552549A Active JP7668742B2 (ja) 2019-03-06 2020-03-06 Ｍｈｃクラスｉｉモデルによる新生抗原の特定
JP2025066884A Pending JP2025114587A (ja) 2019-03-06 2025-04-15 Ｍｈｃクラスｉｉモデルによる新生抗原の特定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025066884A Pending JP2025114587A (ja) 2019-03-06 2025-04-15 Ｍｈｃクラスｉｉモデルによる新生抗原の特定

Country Status (10)

Country Link
US (1) US20220154281A1 (https=)
EP (1) EP3935071A4 (https=)
JP (2) JP7668742B2 (https=)
KR (1) KR20210137110A (https=)
CN (1) CN113711239A (https=)
AU (1) AU2020232844A1 (https=)
CA (1) CA3132041A1 (https=)
IL (1) IL286086A (https=)
TW (1) TWI894138B (https=)
WO (1) WO2020181240A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US11848073B2 (en) * 2019-04-03 2023-12-19 University Of Central Florida Research Foundation, Inc. Methods and system for efficient indexing for genetic genealogical discovery in large genotype databases
SG11202110956RA (en) 2019-04-05 2021-10-28 Rootpath Genomics Inc Compositions and methods for t-cell receptor gene assembly
US11644470B2 (en) * 2019-04-15 2023-05-09 Bioinformatics Solutions Inc. Systems and methods for de novo peptide sequencing using deep learning and spectrum pairs
US11727284B2 (en) * 2019-12-12 2023-08-15 Business Objects Software Ltd Interpretation of machine learning results using feature analysis
WO2022087380A1 (en) * 2020-10-23 2022-04-28 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
CN112910288B (zh) * 2020-12-08 2022-08-09 上海交通大学 一种基于逆变器散热器温度预测的过温预警方法
CN113255690B (zh) * 2021-04-15 2022-04-12 南昌大学 一种基于轻量级卷积神经网络的复合绝缘子憎水性检测方法
CN113160887B (zh) * 2021-04-23 2022-06-14 哈尔滨工业大学 一种融合了单细胞tcr测序数据的肿瘤新生抗原筛选方法
CN116264103A (zh) * 2021-12-14 2023-06-16 深圳华大基因股份有限公司 构建机器学习模型的方法、系统及用途
CN114023387B (zh) * 2022-01-05 2022-04-22 山东建筑大学 一种基于卷积神经网络的细胞反卷积预测方法
WO2023146978A2 (en) * 2022-01-26 2023-08-03 Memorial Sloan-Kettering Cancer Center Systems and methods for determining t-cell cross-reactivity between antigens
CN114446385B (zh) * 2022-01-29 2024-08-13 杭州纽安津生物科技有限公司 Hla ii型分子与多肽的亲和力预测模型的获取方法及装置
WO2023172633A1 (en) * 2022-03-08 2023-09-14 Avalo, Inc. System and method for genomic association
WO2023215358A1 (en) * 2022-05-03 2023-11-09 3T Biosciences, Inc. T-cell target discovery
CN115295084B (zh) * 2022-08-05 2026-03-17 南开大学 一种肿瘤新抗原免疫组库数据可视化分析方法和系统
EP4570907A1 (en) * 2022-08-08 2025-06-18 Sapporo Medical University Method for selecting subject-derived neoantigen
AU2023321890A1 (en) * 2022-08-12 2025-02-27 Biontech Us Inc. Methods and systems for prediction of hla epitopes
EP4680270A1 (en) * 2023-03-13 2026-01-21 Seattle Project Corp. Epitope prediction via a learned genotype network across class ii mhc alleles
CN116469457B (zh) * 2023-06-14 2023-10-13 普瑞基准科技（北京）有限公司 Mhc与抗原多肽结合、呈递及免疫原性的预测模型训练方法和装置
CN117912568B (zh) * 2024-01-05 2024-08-06 中山大学 H9n2亚型禽流感毒株抗原性快速鉴别方法及装置
CN120089201B (zh) * 2025-04-30 2025-07-04 广东省农业科学院动物卫生研究所 一种基于深度学习的通用表位多肽筛选方法和系统
CN120600110B (zh) * 2025-08-06 2025-12-09 上海交通大学医学院附属仁济医院 基于人工智能的多变病原t细胞表位精准筛选方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521128A (ja) 2013-05-10 2016-07-21 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ Ｔ細胞エピトープの免疫原性の予測
WO2018195357A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002038B (zh) * 2014-09-17 2021-10-15 约翰·霍普金斯大学 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
CN109145927A (zh) * 2017-06-16 2019-01-04 杭州海康威视数字技术股份有限公司 一种对形变图像的目标识别方法及装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521128A (ja) 2013-05-10 2016-07-21 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ Ｔ細胞エピトープの免疫原性の予測
WO2018195357A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Deep learning using tumor HLA peptide mass spectrometory datasets improves neoantigen identification，Nature Biotechnology，2018年12月17日，Vol.37, No.1，p.55-63
Immunogenetics，2015年，Vol.67，p.641-650
Isolation and characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T cell receptor for cancer immunotherapy，J. Immunotherapy，2016年，Vol.39, No.5，p.191-201
Machine learning mdethods for predicting HLA-peptide binding activity.，Bioinfomatics and Biology Insights，2015年，Vol.9 (S3)，p.21-29

Also Published As

Publication number Publication date
JP2025114587A (ja) 2025-08-05
TW202100168A (zh) 2021-01-01
EP3935071A4 (en) 2022-12-21
JP2022524328A (ja) 2022-05-02
KR20210137110A (ko) 2021-11-17
US20220154281A1 (en) 2022-05-19
AU2020232844A1 (en) 2021-10-28
IL286086A (en) 2021-10-31
WO2020181240A8 (en) 2021-09-16
CN113711239A (zh) 2021-11-26
CA3132041A1 (en) 2020-09-10
WO2020181240A1 (en) 2020-09-10
EP3935071A1 (en) 2022-01-12
TWI894138B (zh) 2025-08-21

Similar Documents

Publication Publication Date Title
JP7712970B2 (ja) ホットスポットを利用した新生抗原の特定
JP7668742B2 (ja) Ｍｈｃクラスｉｉモデルによる新生抗原の特定
JP7480064B2 (ja) パンアレルモデルによる新生抗原の特定方法
JP7763588B2 (ja) Ｔ細胞療法用の新生抗原の特定法
JP7851893B2 (ja) Ｔ細胞療法用の新生抗原の特定法
HK40034414A (en) Neoantigen identification using hotspots
HK40034414B (en) Neoantigen identification using hotspots
KR20260057650A (ko) T-세포 요법을 위한 신생항원 동정

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250415

R150 Certificate of patent or registration of utility model

Ref document number: 7668742

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150